Recommended criteria for initiating and discontinuing intradialytic parenteral nutrition therapy.
The indications for intradialytic parenteral nutrition (IDPN) in patients with end-stage renal disease remain controversial. Medicare has taken a position to severely limit the use of this form of nutritional therapy. Are there patients who do not meet the government criteria, yet would benefit from this therapy? Studies are required to answer this question, but they may be years away. In the interim, identification of appropriate patients, development of appropriate criteria for initiating and discontinuing therapy, as well as a proper reimbursement process should be considered for the treatment of severe malnutrition in this population of patients. This article discusses these topics and outlines a different approach to the use of IDPN.